The year 2021 witnessed a staggering 529 million diagnosed cases of diabetes, with projections indicating a substantial increase to over 1.31 billion cases by the year 2050 ( GLP-1 RAs are experiencing expanded global utilization and favorable market potential
Victoza for diabetes (up to 1.8 mg), Saxenda for weight management (up to 3 mg) Oral GLP-1 option : Semaglutide (Rybelsus) is the only oral GLP-1 receptor agonist, taken once daily on an empty stomach with specific administration requirements: take with no more than 4 ounces of plain water, at least 30 minutes before eating, drinking, or taking other oral medications, and swallow tablets whole without breaking or chewing
Gonalves A, Marques C, Leal E, Ribeiro CF, Reis F, Ambrsio AF, Fernandes R (2014) Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats
It effectively tells your brain that you are satisfied sooner and for a longer period
Research published in the Journal of Clinical Endocrinology and Metabolism describes the clinical consequences of delayed gastric emptying with both GLP-1 receptor agonists and tirzepatide, noting that the dual GIP/GLP-1 receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists
